Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 5, Number 1—February 1999

The Economic Impact of Staphylococcus aureus Infection in New York City Hospitals

Robert J. Rubin, Catherine A. Harrington, Anna Poon, Kimberly Dietrich, Jeremy A. Greene, and Adil Moiduddin
Author affiliations: The Lewin Group, Fairfax, Virginia, USA

Main Article

Table 5

Direct medical charges—average hospital facility charges, professional fees, and postdischarge costs per case

Type of infection Hospital charges
(%) Professional fees
$ (%) Post-discharge costs
$ (%) Total $
Pneumonia 33,400 (94) 2,000 (6) NDa 35,400
Bacteremia 27,900 (89) 2,100 (7) 1,300 (4) 31,300
Endocarditis 41,700 (88) 4,300 (9) 1,200 (3) 47,200
Surgical site infection 20,200 (93) 1,600 (7) ND 21,800
Osteomyelitis 30,000 (86) 3,200 (9) 1,800 (5) 35,000
Septic arthritis 30,600 (87) 3,100 (9) 1,400 (4) 35,100
Average 29,000 (90) 2,300 (7) 800 (3) 32,100

aND=no data.

Main Article

  1. Haley  RW, Culver  DH, White  JW, Morgan  WM, Emori  TG. The nationwide nosocomial infection rate: a new need for vital statistics. Am J Epidemiol. 1985;121:159.PubMedGoogle Scholar
  2. Pittet  D, Tarara  D, Wenzel  RP. Nosocomial bloodstream infection in critically ill patients, excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598601. DOIPubMedGoogle Scholar
  3. Brachman  PS, Dan  BB, Haley  RW, Hooten  TM, Garner  JS, Allen  JR. Nosocomial surgical infections: incidence and cost. Surg Clin North Am. 1980;60:1525.PubMedGoogle Scholar
  4. Centers for Disease Control and Prevention. National Nosocomial Infection Surveillance System report: data summary from October 1986-April 1996. Atlanta (GA): U.S. Department of Health and Human Services; 1996.
  5. Neu  HC. The crisis in antibiotic resistance. Science. 1992;257:106472. DOIPubMedGoogle Scholar
  6. Barrett  FF, McGehee  RF, Finland  M. Methicillin-resistant Staphylococcus aureus at Boston City hospital. N Engl J Med. 1968;279:441.PubMedGoogle Scholar
  7. Boyce  JM. Increasing prevalence of methicillin-resistant Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol. 1990;11:63942. DOIPubMedGoogle Scholar
  8. Panlilio  AL, Culver  DH, Gaynes  RP, Banerjee  S, Henderson  TS, Tolson  JS, Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol. 1992;13:5826. DOIPubMedGoogle Scholar
  9. Nosocomial enterococci resistant to vancomycin—United States, 1989-1993. MMWR Morb Mortal Wkly Rep. 1993;42:5979.PubMedGoogle Scholar
  10. Recommendations for preventing the spread of vancomycin resistance recommendations of the Hospital Infection Control Practices Advisory Committee. MMWR Morb Mortal Wkly Rep. 1995;44(RR12):113.PubMedGoogle Scholar
  11. Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:6246.PubMedGoogle Scholar
  12. Update: Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. MMWR Morb Mortal Wkly Rep. 1997;46:8135.PubMedGoogle Scholar
  13. Boyce  JM, Jackson  MM, Pugliese  G, Batt  MD, Fleming  D, Garner  JS, Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. Infect Control Hosp Epidemiol. 1994;15:10515. DOIPubMedGoogle Scholar
  14. McManus  AT, Mason  AD, McManus  WF, Pruitt  BA. What's in a name? Is methicillin-resistant Staphylococcus aureus just another S. aureus when treated with vancomycin? Arch Surg. 1989;124:14569.PubMedGoogle Scholar
  15. Pittet  D, Waldvogel  FA. To control or not to control colonization with MRSA…that's the question! QJM. 1997;90:23941. DOIPubMedGoogle Scholar
  16. Teare  EL, Barrett  SP. Stop the ritual of tracing colonised people. BMJ. 1997;314:6656.PubMedGoogle Scholar
  17. Cookson  B. Controversies: is it time to stop searching for MRSA? Screening is still important. BMJ. 1997;314:6645.PubMedGoogle Scholar
  18. Casewell  MW. New threats to the control of methicillin-resistant Staphylococcus aureus. J Hosp Infect. 1995;30(Suppl):46571. DOIPubMedGoogle Scholar
  19. Jarvis  WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol. 1996;17:5527. DOIPubMedGoogle Scholar
  20. Haley  RW, White  JW, Culver  DH, Hughes  JM. The financial incentive for hospitals to prevent nosocomial infections under the prospective payment system: an empirical determination from a nationally representative sample. JAMA. 1987;257:16114. DOIPubMedGoogle Scholar
  21. Wakefield  DS, Pfaller  MA, Hammons  GT, Massanari  RM. Use of the appropriateness evaluation protocol for estimating the incremental costs associated with nosocomial infections. Med Care. 1987;25:4818. DOIPubMedGoogle Scholar
  22. Jernigan  JA, Clemence  MA, Stott  GA, Titus  MG, Alexander  CH, Palumbo  CM, Control of methicillin-resistant Staphylococcus aureus at a university hospital. Infect Control Hosp Epidemiol. 1995;16:68696. DOIPubMedGoogle Scholar
  23. Wakefield  DS, Helms  CM, Massanari  RM, Mori  M, Pfaller  M. Cost of nosocomial infection: relative contributions of laboratory, antibiotic and per diem costs in serious Staphylococcus aureus infections. Am J Infect Control. 1988;16:18592. DOIPubMedGoogle Scholar
  24. Frieden  TR, Fujiwara  PI, Washko  RM, Hamburg  MA. Tuberculosis in New York City—turning the tide. N Engl J Med. 1995;333:22933. DOIPubMedGoogle Scholar
  25. Frieden  TR, Munsiff  SS, Low  DE, Willey  BM, Williams  G, Faur  Y, Emergence of vancomycin-resistant enterococci in New York City. Lancet. 1993;342:769. DOIPubMedGoogle Scholar
  26. New York State Department of Health. 1995 Statewide Planning and Research Cooperative System (SPARCS) Administratively Releasable File. Albany (NY): The Department; 1997.
  27. Health Care Financing Administration. Physician fee schedule (CY 1995); payment policies and relative value adjustments. Fed Regist. 1994;59:63410635.PubMedGoogle Scholar
  28. 1995 Drug Topics Red Book. Montvale (NJ): Medical Economics Company; 1995.
  29. International classification of diseases, 9th revision, clinical modifier: with color symbols: ICD-9-CM. 4th ed. Salt Lake City (UT): Medicode Publications; 1994.
  30. Lautenschlager  S, Herzog  C, Zimmerli  W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis. 1993;16:56773.PubMedGoogle Scholar
  31. Espersen  F. Identifying the patient risk for Staphylococcus aureus bloodstream infections. J Chemother. 1995;7:117.PubMedGoogle Scholar
  32. Muder  R, Brennen  C, Wagener  M, Goetz  A. Bacteremia in a long-term care facility: a five year prospective study of 163 consecutive episodes. Clin Infect Dis. 1992;14:64754.PubMedGoogle Scholar
  33. Mandell  GI, Bennett  JE, Dolin  R, eds. Mandell, Douglas and Bennett's principles and practices of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995.
  34. Lavery  LA, Sariaya  M, Ashry  H, Harkless  LB. Microbiology of osteomyelitis in diabetic foot ulcers. J Foot Ankle Surg. 1995;34:614. DOIPubMedGoogle Scholar
  35. Isselbacher  KJ, Braunwald  E, Wilson  JD, Martin  JB, Fauci  AS, Kasper  DL, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, Inc.; 1994.
  36. Fagon  JY, Chastre  J, Vuagnat  A, Troillet  JL, Novara  A, Gibert  C. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA. 1996;275:8669. DOIPubMedGoogle Scholar
  37. Papazian  L, Bregeon  F, Thirion  X, Gregoire  R, Saux  P, Denis  JP, Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med. 1996;154:917.PubMedGoogle Scholar
  38. Fagon  JY, Chastre  J, Hance  AJ, Montravers  P, Novara  A, Gibert  C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med. 1993;94:2818. DOIPubMedGoogle Scholar
  39. Leu  HS, Kaiser  DL, Mori  M, Woolson  RF, Wenzel  RP. Hospital-acquired pneumonia: attributable mortality and morbidity. Am J Epidemiol. 1989;129:125867.PubMedGoogle Scholar
  40. Craven  PC. Treating bone and joint infections with teicoplanin: hospitalization vs. outpatient cost issues. Hosp Formul. 1993;28:415.PubMedGoogle Scholar
  41. Allen  R. Cost-effectiveness issues for home IV therapy in the United States. Hosp Formul. 1993;28:3740.PubMedGoogle Scholar
  42. Arnow  PM, Quimosing  EM, Beach  M. Consequences of intravascular catheter sepsis. Clin Infect Dis. 1993;16:77884.PubMedGoogle Scholar
  43. Agency for Health Care Policy and Research. The HCUP-3 Nationwide Inpatient Sample (NIS), Release 2, 1993. Springfield (VA): National Technical Information Service; 1996.
  44. Bradley  SF. Methicillin-resistant Staphylococcus aureus infection. Clin Geriatr Med. 1992;8:85368.PubMedGoogle Scholar
  45. McEvoy  GK, ed. American hospital formulary service drug information 1997. Bethesda (MD): American Society of Health-System Pharmacists; 1997.
  46. Spink  WW. Staphylococcal infections and the problem of antibiotic-resistant staphylococci. Arch Intern Med. 1954;94:16796.
  47. Allen  JD, Roberts  CE, Kirby  WM. Staphylococcal septicemia treated with methicillin: report of twenty-two cases. N Engl J Med. 1962;266:1116.PubMedGoogle Scholar

Main Article

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.